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Abstract 
Background 
Ascertaining the acceptability of healthcare provision to service users is an important factor 
in promoting service uptake, especially for populations who are reluctant to access care. 
This study identified the attributes of a Hepatitis C (HCV) testing service for people 
prescribed Opioid Substitution Therapy (OST) and used their expressed preferences to 
guide design of a service, using an applied health economics approach. 
Materials and Methods 
Preferences of OST users were elicited using a discrete choice experiment.  Important 
attributes for HCV testing were partly pre-determined by the research question and also 
identified using literature review and focus groups. Predetermined attributes included choice 
of provider and financial incentives. Other important attributes were place of testing; travel 
distance; attitudes and staff undertaking testing; waiting time for test results and incentive 
payment.  The relative importance of defined attributes was assessed in 103 OST users 
attending 6 pharmacies from Dundee. 
Results 
OST users preferred testing at their “own pharmacy”, by their drug worker, followed by their 
general practitioner (GP).  Use of another pharmacy was the least preferred option. Being 
treated with dignity and respect was valued most highly, with waiting time for test results and 
travel distance also important.  Financial incentives were not considered important. 
Conclusions 
This study provides evidence that OST users prefer testing at their own pharmacy.  The 
addition of a pharmacy to the providers offering HCV testing may increase uptake and 
support policies to eliminate HCV from our communities.  Being treated with dignity and 
respect was highly valued and this suggests that testing uptake can be increased by 
developing positive relationships between OST users and test providers. Financial incentives 
were not found to be important. 
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Introduction 
The World Health Organisation Guidelines on Testing for Hepatitis B and C establish critical 
enablers for the provision of efficient and effective services. Suggested best practice 
includes implementation of simplified, decentralised care pathways, with task-shifting to non-
specialised staff (WHO 2017).  Additionally such services should be delivered in a way that 
is acceptable to service users, especially for populations who are reluctant to access care. It 
is important also to consider testing as part of the continuum of care to HCV cure rather than 
an isolated step (WHO 2016). 
In developed countries, people who inject drugs (PWIDs) are the major group affected by 
hepatitis C (HCV) infection (WHO 2016). In communities where heroin is the principle drug 
injected research suggests that around 40% of people prescribed Opioid Substitution 
Therapy (OST) are infected (Aspinall, Doyle, Corson, Hellard, Hunt, Goldberg...Hutchinson 
2015; Edlin, Kresina, Raymond, Carden, Gourevitch, Cheever, Cargill 2005).  In current HCV 
testing and treatment pathways within the United Kingdom, less than 10% of the OST 
population are tested for HCV and a similar pattern is seen across the world: a depressing 
repetition of waterfall plots shows people with HCV infection are lost to care at each step 
(Iveson, Grebely, Catlett, Cunnigham, Dore, Maher 2017). 
The barriers that prevent uptake of HCV testing and treatment have been characterised as 
system-level, practitioner-level and patient level (Grebely, Oser, Taylor, Dore 2013). At the 
system level services may still be based on a configuration designed to identify people 
suitable for interferon based treatment, with conventional pathways containing multiple steps 
(Arora, Thornton, Murata, Deming, Kalishman, Dion... Qualls 2011). These pathways may be 
further complicated by required actions by specific practitioners allowing access to services 
or remuneration for those services. At the practitioner level these restrictions also apply. 
Prejudice against PWIDs also operates with many practitioners having the expectation that 
people will not adhere to medical treatment. Health practitioners may not perceive HCV 
treatment as a legitimate activity within their practice and may not have the necessary skills 
and knowledge to be confident in discussing HCV treatment with the client group (Treolar, 
Newland, Rance and Hopwood 2010).  At the patient level, people taking methadone may 
live in poverty and experience stigmatising and discriminating behaviour (O'Gorman, 
Driscoll, Moore, Roantree 2016). The need to travel to attend clinics decreases the numbers 
of people being tested (Astell-Burt, Flowerdew, Boyle, Dillon 2011; Monnet, Ramee, Minello, 
Joost, Carel, Di Martino 2008; Papatheodoridis, Tsochatzis, Hardtke, Wedeyer 2014) and 
proximity to services may be more important in rural communities.  People who inject drugs 
may have shifting priorities between HCV treatment and other activities, may not have the 
relevant information about the treatment efficacy and side-effects of Direct Acting Antiviral 
(DAA) Medicines, may not seek out testing and treatment and may experience anxiety and 
confusion when offered opportunistic testing (Jones, Atkinson, Bates, McCoy, Porcellato, 
Beynon...Bellis 2014).  Low levels of health literacy may limit understanding of their health, 
illness and treatments (Kalichman, Benotsch, Suarez, Catz, Miller, Rompa 2000). 
Delivery of HCV testing and treatment through community-based care pathways has been 
shown to be feasible (Wade, Veronese, Hellard, Doyle 2016) and dried blood spot testing 
(DBST) has been demonstrated to increase the uptake of testing from high-risk populations 
(Coats & Dillon 2015; Taheri 2010; McAllister, Innes, Mcleod, Dillon, Hayes, Fox 2014).  
Testing in community environments in risk groups, can result in high levels of linkage to care 
(Tait, Stephens, McIntyre, Evans, Dillon 2013).  The use of DBST in non-traditional 
environments has dramatically increased detection of HCV (Morana, Zelenev, Lombard, 
Marcus, Gibson, Altice 2014).  
With appropriate training HCV testing can be carried out by a range of personnel, including 
community pharmacists (The Hepatitis C Trust 2016).  Pharmacy provision has particular 
potential for the OST population as they have daily interactions with pharmacies.  However, 
little is known about whether OST users would find testing at pharmacies acceptable and 
what other aspects of testing are important to them.  To optimise uptake, it is crucial that 
HCV testing is designed in line with users’ preferences (WHO 2016). 
In this study, a Discrete Choice Experiment (DCE) was used to elicit the preferences of 
service users who access OST from pharmacies, to help co-produce the design of an HCV 
testing service.  DCEs are a commonly used stated preference technique for eliciting patient 
preferences for healthcare services in order to understand what attributes of a service are 
important and the relative importance of these attributes (Kjaer 2005). 
The design of a service often requires trade-offs between attributes that are important to 
patients.  For example, HCV testing can be provided at a pharmacy but the waiting time to 
test results may be longer compared to HCV testing by GPs.  DCEs can elicit and quantify 
how patients make trade-offs between these attributes.  DCEs are rooted in Lancaster’s 
theory which relates the utility or value of goods and services to the characteristics or 
attributes of the goods or services.  DCEs present individuals with a series of hypothetical 
choices between different service configurations which vary in a number of characteristics or 
attributes (for example location of testing, waiting time etc).  DCEs are also based on 
random utility theory (RUT) which means that the choice behaviour of individuals is assumed 
to be probabilistic rather than deterministic.  This means that the utility (or value) of the 
healthcare service has a systematic component (such as the attributes) that can explain the 
choices individuals make within the DCE and a random component which include 
unobserved factors that can explain choices such as psychological factors.   
A DCE approach has recently been used to elicit service user preferences for HCV 
treatment efficacy, the occurrence of adverse treatment effects and the degree of treatment 
burden (Mühlbacher, Bridges, Bethge and Nubling 2017). However no work has been 
identified that considers service users’ preferences in terms of HCV testing and how they 
may trade off the different attributes of the testing, such as provider (location), travel 
distance and waiting time for results.  The use of DCEs to predict uptake of treatment for 
new pathways of care is also a useful feature of this technique when addressing the need to 
deliver on the ambition to eliminate hepatitis C as a public health concern (Quaife, Terris-
Presholt, Di Tanna, Vickerman 2018) 
Materials and methods 
The aim of this discrete choice experiment was to elicit OST user’s preferences for HCV 
testing, in order to aid the design of a testing service that was acceptable to use from their 
perspective.  The attributes and levels in the DCE were selected following recommended 
practice (Reed Johnson, Lancsar, Marshall, Kilambi, Mühlbacher, Regier...Bridges 2013).  A 
number of attributes were predetermined by the research question.  The aim of the DCE was 
to examine whether OST users may prefer HCV testing in pharmacy over other settings and 
provider of testing was therefore a pre-determined attribute.  We were also interested in 
assessing the potential of using financial incentives, therefore financial incentive was also a 
pre-determined attribute (WHO 2016). A review of existing literature was undertaken to 
identify other attributes of HCV testing that are important to individuals.  The themes 
identified through this process included medical and community clinic provision; travel 
distance from the clinic; the requirement for attendance at a remote site; the experience of 
stigmatising behaviour; the use of point of care testing and difficulties with taking venous 
samples (Wade, Veronese, Hellard, Doyle 2016; Harris and Rhodes 2013; Arain and 
Robaeys 2014; Jones, Atkinson, Bates, McCoy, Porcellato, Beynon...Bellis 2014).  
Focus Group Series 
In order to test the relevance of these possible attributes to the target group and to explore 
whether there were any other important attributes, a focus group series was undertaken with 
service users to establish their views of current services and especially of their experiences 
of using community pharmacies to access care (Radley, Melville, Easton, Williams and 
Dillon 2016).  Seven focus groups with a total of 41 participants (Table 1) were undertaken 
during 2015, in a range of settings, aiming to gain a diversity of views and experiences, until 
no new data (saturation) were achieved. Participants were people prescribed OST by the 
specialist substance misuse service in Tayside, who provide the majority of care for this 
group. Participants discussed comparative experiences of partners, family and associates 
who had undertaken testing and treatment for HCV. 
Recruitment to the focus groups concentrated on the following variables:  
 Place of Residence –large urban / other urban / accessible small town 
 Service Users detained by the Criminal Justice System 
 Perspectives of male and female service users 
 Perspectives of peer mentors (service users at an advanced stage of recovery) 
Sessions were open-ended and ranged from 70–100 minutes.  The first focus group served 
as an internal pilot to test the discussion guide.  The seventh focus group with peer mentors 
was undertaken to provide perspective on the findings from this study. In the local service 
configuration, peer mentors are experienced service users who have received ORT for a 
number of years and are further along a recovery pathway: we listened to their reflections 
and perspectives on the themes that had emerged. 
Data from each focus group were digitally recorded and transcribed verbatim, before being 
coded and analysed by two researchers.  Analysis drew on the constant comparison 
method, which was operationalised within a general thematic approach (Richie and Spencer 
1994).  
Focus group participants described a range of attributes that had significant overlap with 
those identified from the literature: stigma, waiting times, confidentiality of results and 
positive relationships with service providers. 
The final attribute list included the pre-determined attributes (who does the testing (provider) 
and incentive payment) as well as the most important other attributes identified through the 
literature review and focus groups (whether treated with dignity and respect; travel distance; 
and waiting time to test results).  The larger the number of attributes, the greater the 
cognitively complexity of the DCE and therefore the total number of attributes was kept to a 
manageable level.  Plausible levels were assigned to each attribute based on focus group 
responses and the local context for factors such as laboratory turnaround and travel 
distance.  Table 2 presents the attributes and their levels.  Figure 1 shows an example of a 
discrete choice scenario considered by participants. 
Given the number of attributes and their levels, the total number of possible combinations is 
equal to 512. This was reduced to 16 choice sets using a D-efficient main effects design with 
flat priors created in SAS (Statistical Analysis Software) (Burges, L and Street D 2005).  An 
opt-out was included in each choice set.  The design is presented in Appendix 1. 
Design of the Questionnaire 
The final study questionnaire contained three sections: Section 1 ascertained participants’ 
preferences on the levels within the 5 attributes; Section 2 presented the 16 discrete 
choices; Section 3 collected details of patient demography including age, sex, educational 
level and employment.  The cognitive burden of the choice sets in the questionnaire was of 
especial concern, because of awareness of potential issues with comprehension, literacy 
levels and attention spans in the respondent group (Borisova and Goodman 2004).  Think 
aloud interviews were undertaken with 7 individuals to test the wording and check the 
understanding of the questionnaire design.  Respondents completed the questionnaire in the 
presence of one of the researchers who provided support where required (Kronenberg, 
Slager-Visscher, Goossens, van den Brink, van Achterberg 2014).  The administration of the 
questionnaire in a familiar environment was also chosen, to reduce participant stress and 
enable access. 
A total of 103 participants within six pharmacies in Dundee City that they used to access 
OST completed the questionnaire.  All participants completed a consent form before 
completing the questionnaire.  
Estimation procedure 
In each choice set an individual was presented with a choice between three options (j): test 
A, test B or no test.  It assumed that individuals will choose the option that they value most 
highly, that is, the option they receive the highest utility from.    
The utility that an individual (i) receives from an option (Vij) is a function of the attributes and 
levels included in the DCE: 
 
𝑉𝑖𝑗 = ( 𝛽0 + 𝜎0)𝑇𝑒𝑠𝑡𝑖𝑗 + ( 𝛽1 + 𝜎1)𝑂𝑡ℎ𝑒𝑟 𝑝ℎ𝑎𝑟𝑚𝑎𝑐𝑦𝑖𝑗 + ( 𝛽2 + 𝜎2)𝐺𝑃𝑖𝑗 +  ( 𝛽3 +
𝜎3)𝐷𝑟𝑢𝑔𝑊𝑜𝑟𝑘𝑒𝑟𝑖𝑗 + ( 𝛽4 + 𝜎4)𝑅𝑒𝑠𝑝𝑒𝑐𝑡𝑖𝑗 +  ( 𝛽5 + 𝜎5)𝑇𝑟𝑎𝑣𝑒𝑙𝑖𝑗 +  𝛽6𝑇𝑖𝑚𝑒𝑖𝑗+ ( 𝛽7 +
𝜎7)𝑀𝑜𝑛𝑒𝑦𝑖𝑗 + 𝜀𝑖𝑗 
“Test” is the alternative specific constant which takes on the value of 1 if the option is either 
Test A or Test B and 0 if the option is No test.  “Other pharmacy”, “GP” and “Drug worker” 
are the provider, “Respect” is whether treated with dignity and respect, “Travel” is the travel 
distance in miles, “Time” is the waiting time for results in weeks and “Money” is the amount 
of money they receive if they take the test in pounds and ij is the random error term.  β and 
 are the parameters to be estimated.  The βs represent the average marginal utility of 
changes in the attribute.  These can be interpreted as follows.  For the quantitative 
attributes, a one unit increase (for example, a 1 week increase in waiting time) reduces utility 
by the size of the β.  The qualitative attributes (provider and respect) are modelled using 
dummy coding.  In this case the coefficients represent the difference in utility between the 
attribute level (for example drug worker) and the base category (for example own 
pharmacy). The s represent the individual specific preference variation for the attributes.  A 
statistically significant  indicates that individuals vary in terms of how they value the 
attribute.  The distribution of the coefficients was assumed to be normal.  A fixed parameter 
was assumed for waiting time to stabilise the estimation process and allow for easier 
estimation of the willingness to wait (see below).  This means that respondents were 
assumed to have the same negative preference for waiting time.  The model was estimated 
using mixed logit regression in Stata using maximum simulated likelihood with 3000 Halton 
draws. 
The relative importance of the attributes was assessed by estimating willingness to wait, 
calculated by dividing the estimated coefficient values of the attributes with the coefficient 
value of the waiting time attribute.  This indicates how much longer individuals are willing to 
wait for a unit change in an attribute.  For example, (β4/-β6) indicates how much longer 
individuals are willing to wait for their test results if they are treated with dignity and respect.   
 
Results 
The sample characteristics of the respondents completing the discrete choice questionnaire 
are shown in Table 3. The sample closely mirrors the characteristics found in OST 
population in Dundee for the parameters of age (median age range 30-40 years), 
educational level (completed secondary school) and employment (registered unemployed or 
unable to work due to disability).  The sample however contains approximately fifty per cent 
female respondents, whereas females represent around a third of the base population.   
Test A was chosen in 39.5% of choice sets, Test B in 48.8% of choice sets and in 11.6% of 
choice sets the respondents chose no test.  Analyses of the “No Test” option identified that 
68% of respondents did not choose this option for any of the discrete choice sets.  Three 
percent of the respondents selected “No Test” for between 13 and 16 of the discrete choice 
sets. 
Table 4 shows the regression results.  The results show that individuals prefer to be tested 
at their own pharmacy.  The coefficient on drug worker is not statistically significant 
indicating that own pharmacy and drug worker are equally preferred.  Other pharmacy is the 
least preferred option.  Being treated with dignity and respect, waiting time for test results 
and travel distance are all important to individuals.  The sign of the coefficients is as 
expected with OST respondents preferring to be treated with dignity and respect, shorter 
travel distance and shorter waiting times for tests results.  Money received is not significant 
suggesting that the use of financial incentives may not increase uptake of testing.  There 
was statistically significant preference variation for provider (other pharmacy, GP and drug 
worker) and being treated with dignity and respect.  There was no significant preference 
variation for travel distance or money received.  Further analysis (including latent class 
modelling) suggested that preference heterogeneity was not associated with any of the 
observed individual characteristics  
Table 5 provides further insights into the relative importance of the attributes by estimating 
the willingness to wait.  Being treated with dignity and respect is of particular importance to 
individuals.  They are willing to wait an additional 9.2 weeks for their test result if they are 
treated with dignity and respect.  They are willing to wait an additional 3.9 weeks for their 
test result if the test is taken at their own pharmacy instead of another pharmacy and 2.4 
weeks if the test if taken at their own pharmacy instead of their GP. 
Discussion 
This study has examined OST users’ preferences for hepatitis C testing using a discrete 
choice experiment, as a method to increase the acceptability of healthcare provision to 
service users (WHO 2017). It provides supporting evidence of the importance of considering 
a range of factors when working to improve treatment access (Harris and Rhodes 2013). 
The results indicate that individuals prefer to be tested at their own pharmacy or by their 
drug worker.  These two options are preferred to testing by GP or other pharmacy.  Being 
treated with dignity and respect was the most important attribute with waiting time for test 
results and travel distance also being important to individuals.  Being treated with dignity and 
respect was found to be the most important attribute for test decision making. 
In this study, money received did not have a significant effect, suggesting that the use of 
financial incentives may not increase uptake of testing.  However, it may be the case that 
respondents in our DCE ignored the incentives attribute because payments to produce 
changes in health behaviour remain controversial; individuals feel shame in accepting 
money for treatment of their stigmatised condition.  Monetary incentives have been found to 
be helpful in promoting testing for HIV (Rakotonarivo, Schaafsma, Hockley 2016); a recent 
study has found that financial incentives could be applied to support treatment adherence in 
HCV care (Wohl, Allmon, Evon, Hurt, Reifeis, Thirumurthy...Mollan 2017).  A small pilot 
study of incentives to promote HCV testing in a prisoner and parole population found little 
discernible effect from offering incentives (Grebely, Oser, Taylor and Dore 2013).  This is in 
line with our DCE results but further evidence on the effectiveness of incentives in HCV 
testing is clearly required. 
This study adopted accepted best practice in the use of qualitative methods to inform 
attribute selection (Zaller, Patry, Bazerman, Noska, Kuo, Kurth, Beckwith 2016; Kjaer 2005).  
The use of focus groups provided the researchers with a range of perspectives on the 
experiences of methadone users when using pharmacies as a service.  The focus group 
series identified time as one of the important attributes.  The value of time has previously 
been assessed in patients prescribed OST (Clark, Determann, Petrou, Moro, Bekker-Grob 
2014) and is thought to be a good method of measuring relative importance.  We used 
willingness to wait for test results as a ‘currency’ for expressing the relative importance of the 
different attributes of HCV testing.  Willingness to wait has also been used with this patient 
group to evaluate treatment attendance (Borisova and Goodman 2003). 
Respondents in the focus group series reacted strongly to the issue of stigma and 
discrimination.  This finding was also identified in the subsequent discrete choice 
experiment, where a service in which respondents were treated with respect was valued 
highly.  This suggests that getting providers to develop more positive relationships with OST 
users may be the most effective way to increase uptake of HCV testing.  
A number of limitations are noted for this study.  Firstly, the DCE choices were hypothetical.  
Individuals’ real choices (the choices they would make in real life) may not always be the 
same as the choices they make in a hypothetical DCE.  This is referred to as hypothetical 
bias and is a general limitation of DCEs.  However, a recent review suggests that DCEs can 
make reasonable predictions of health related behaviour (Quaife, Terris-Presholt, Di Tanna, 
Vickerman 2018).  Secondly, the lived experience of stigma was pre-dominant in the focus 
group discussions and also the most important attribute within the DCE.  The strength of this 
response meant that being treated with dignity and respect was the first concern of 
participants and may have been a dominant attribute within the DCE.  As a result the other 
attributes may have had little or no impact on decision-making.  As it is not possible to 
robustly assess whether any of the attributes are dominant within a DCE (Lanscar and 
Louviere 2006), this should be explored further using qualitative research. 
The cognitive burden of the choice sets questionnaire was carefully assessed by the 
authors, who were cognisant of potential issues with literacy, comprehension and attention 
span (Kronenberg, Slager-Visscher, Goossens, van den Brink, van Achterberg 2014).  The 
method requires that the participant makes a series of decisions between a series of sixteen 
alternatives, in order to estimate which attributes are most important in decision-making.  
Strategies such as administration of the questionnaire by one of the authors, was used to 
ensure that respondents were able to provide accurate responses.  Female participants 
were relatively over-represented amongst those choosing to take part in the DCE.  The 
choice-set questionnaires were administered in the consulting rooms of pharmacies, where 
the female participants could obtain privacy to express their views. 
DCEs ask respondents to make hypothetical choices.  Disparities between revealed and 
stated preferences have been termed hypothetical bias.  Hypothetical bias may originate 
from a number of sources, including where choice tasks do not fully reflect reality, where 
respondents have incomplete preferences or if respondents perceive a vested interest in 
over- or under- reporting the importance of particular attributes (Quaife, Terris-Presholt, Di 
Tanna, Vickerman 2018).  Such an effect may be important for respondents where the lived 
experience of stigma is such an important factor in decision making. 
Conclusion 
Provision of simplified, decentralised care for treatment of HCV is one of the key enablers for 
achieving the WHO target for HCV elimination (WHO 2016).  The use of task sharing with 
non-HCV specialists is also important to increase the service capacity available for care 
provision. This study demonstrates the acceptability for provision of testing in community 
pharmacies and evidence that the addition of a pharmacy to the range of providers offering 
testing can make a contribution to the elimination of Hepatitis C from our communities.  
Being treated with dignity and respect was clearly the most important attribute of a testing 
service and this study provides evidence that uptake of HCV testing can be increased by 
developing more positive relationships between OST users and providers. 
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Table 1 – Focus group participant profile 
  Number of Participants 
Age group at participation Less than 35 years 
35 – 44 years 
45 – 54 years 
Over 55 years 
Did not disclose 
17 
5 
6 
4 
9 
Sex Male 
Female 
31 
10 
Participant category Service User 
Carer 
38 
3 
Focus Group Venue Large Urban Settlement 
Other Urban Settlement 
Accessible Rural Town 
Prison Educational Centre 
Women’s Group 
Peer Mentor’s Group 
10 
10 
6 
7 
4 
4 
 
  
Table 2 Definition of attributes and Levels 
Time  Distance  Money 
received  
Provider  Dignity/Respect  
1 week  0.5 miles  0  GP  Yes  
2 weeks  1 miles  £2  Drug Worker  No  
3 weeks  2 miles  £6  Usual Pharmacy   
4 weeks  4 miles  £12  Other Pharmacy   
 
  
Table 3: Sample characteristics for discrete choice experiment questionnaire 
 N % 
Gender   
   Male 52 50.5 
   Female 51 49.5 
Age   
Age 20-30 11 10.7 
Age 30-40 54 52.4 
Age 40-50 32 31.1 
Age >50 6 5.8 
Education   
Secondary school 65 31.6 
Other professional or technical 
qualification after leaving school 32 15.5 
University degree 5 2.4 
Missing 1 0.5 
Employment status   
Employed 12 11.7 
Unemployed and seeking work 44 42.7 
Unable to work due to illness or 
disability 45 43.7 
Retired 1 1.0 
Missing 1 1.0 
 
 Table 4:  Regression results for the discrete choice experiment 
 
 
Coefficient 
(β) 
p-value Standard 
deviation 
of the 
random 
parameters 
() 
p-value Difference 
in utility 
between 
best and 
worst level 
Relative 
size of 
utility 
difference 
       
Test 4.1687 <0.001 4.0466 <0.001   
Test location     0.959 21.7% 
   Other pharmacy -0.9240 <0.001 1.1801 <0.001   
   GP -0.5518 0.002 0.9328 <0.001   
   Drug worker 0.0348 0.835 0.7130 <0.001   
Treated with dignity and respect 2.1515 <0.001 1.9891 <0.001 2.152 48.7% 
Travel distance (miles) -0.2345 <0.001   0.704 15.9% 
Waiting time for results (weeks) -0.1138 0.003   0.398 9.0% 
Money received (£) 0.0174 0.104   0.209 4.7% 
N 4932      
Pseudo R2 0.2739      
AIC 2005.354      
 
 
 
 
 
 Table 5: Willingness to wait analysis  
WTW Additional weeks willing to 
wait for test result 
 Mean 95% confidence 
interval* 
Having test at own rather than other pharmacy 3.9 1.8 - 6.1 
Having test at own pharmacy rather than GP 2.4 0.7 - 4.0 
Having test at own pharmacy rather than drug worker 0.1 -1.3 - 1.6 
Being treated with dignity and respect 9.2 4.9 - 13.5 
Reduce travel distance by 1 mile 0.5 0.1 - 0.8 
Receive an additional £1 for taking test 0.1 0.0 - 0.2 
* estimated using the delta method 
 
 
 
  
Figure 1 Example of choice set 
 
 
  
 
  Test A Test B  
 
 Where?  Your Usual 
Pharmacy 
Your GP  
 Treated with Dignity 
& Respect? 
YES NO 
 Travel Distance? Half a Mile 2 miles 
 Time to get Results? Two weeks One Week 
 £ You Receive? £2 £4 
 
 
Which Test Would You 
Take? ( only one) 
 Test A Test B No Test  
  
   
Appendix 1.  DCE design 
Option Choice Provider Respect Distance Wait Money 
Test A 1 Drug worker No 4 4 2 
Test B 1 Other pharmacy Yes 2 2 6 
Test A 2 GP No 1 2 0 
Test B 2 Own pharmacy Yes 2 3 12 
Test A 3 Other pharmacy No 2 1 2 
Test B 3 Drug worker Yes 1 2 6 
Test A 4 Other pharmacy Yes 0.5 2 2 
Test B 4 Drug worker No 2 4 0 
Test A 5 Other pharmacy Yes 1 4 0 
Test B 5 GP No 4 1 6 
Test A 6 GP Yes 4 3 0 
Test B 6 Drug worker No 1 1 2 
Test A 7 Other pharmacy Yes 4 3 6 
Test B 7 GP No 2 2 12 
Test A 8 Drug worker Yes 2 3 0 
Test B 8 Own pharmacy No 4 4 12 
Test A 9 Other pharmacy No 4 2 0 
Test B 9 GP Yes 0.5 4 6 
Test A 10 GP No 0.5 3 12 
Test B 10 Own pharmacy Yes 4 2 2 
Test A 11 Other pharmacy Yes 1 1 12 
Test B 11 Own pharmacy No 2 2 6 
Test A 12 GP No 1 1 6 
Test B 12 Drug worker Yes 0.5 2 12 
Test A 13 Drug worker No 0.5 3 2 
Test B 13 Own pharmacy Yes 1 4 12 
Test A 14 GP Yes 1 3 2 
Test B 14 Other pharmacy No 0.5 4 6 
Test A 15 Own pharmacy No 1 3 2 
Test B 15 Drug worker Yes 4 1 12 
Test A 16 GP Yes 2 4 2 
Test B 16 Own pharmacy No 1 3 12 
 
